Zarnegar-Lumley S, Caldwell K, Rubnitz J
Leukemia. 2022; 36(8):1951-1960.
PMID: 35668109
DOI: 10.1038/s41375-022-01619-9.
Petti A, Khan S, Xu Z, Helton N, Fronick C, Fulton R
Blood Cancer Discov. 2022; 3(1):32-49.
PMID: 35019859
PMC: 9924296.
DOI: 10.1158/2643-3230.BCD-21-0050.
Duchmann M, Laplane L, Itzykson R
Cancers (Basel). 2021; 13(19).
PMID: 34638371
PMC: 8507870.
DOI: 10.3390/cancers13194887.
Rimando J, Christopher M, Rettig M, Dipersio J
J Clin Oncol. 2021; 39(5):386-396.
PMID: 33434062
PMC: 8462627.
DOI: 10.1200/JCO.20.01587.
Vosberg S, Greif P
Genes Chromosomes Cancer. 2019; 58(12):839-849.
PMID: 31478278
PMC: 6852285.
DOI: 10.1002/gcc.22806.
Detection of prognostic methylation markers by methylC-capture sequencing in acute myeloid leukemia.
Li Y, Zhao H, Xu Q, Lv N, Jing Y, Wang L
Oncotarget. 2018; 8(66):110444-110459.
PMID: 29299160
PMC: 5746395.
DOI: 10.18632/oncotarget.22789.
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang C, Yan Z, Pascual B, Jackson-Fisher A, Huang D, Zong Q
Neoplasia. 2017; 20(1):1-11.
PMID: 29172076
PMC: 5702869.
DOI: 10.1016/j.neo.2017.10.008.
Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia.
Li Y, Xu Q, Lv N, Wang L, Zhao H, Wang X
J Hematol Oncol. 2017; 10(1):41.
PMID: 28153026
PMC: 5290606.
DOI: 10.1186/s13045-017-0409-z.
Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease.
Kim H, Seol Y, Song M, Choi Y, Shin H, Park S
Blood Res. 2016; 51(3):175-180.
PMID: 27722128
PMC: 5054249.
DOI: 10.5045/br.2016.51.3.175.
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.
Li S, Garrett-Bakelman F, Chung S, Sanders M, Hricik T, Rapaport F
Nat Med. 2016; 22(7):792-9.
PMID: 27322744
PMC: 4938719.
DOI: 10.1038/nm.4125.
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.
Ding L, Ley T, Larson D, Miller C, Koboldt D, Welch J
Nature. 2012; 481(7382):506-10.
PMID: 22237025
PMC: 3267864.
DOI: 10.1038/nature10738.
Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene.
Friedmann M, Holth L, Zoghbi H, Reeves R
Nucleic Acids Res. 1993; 21(18):4259-67.
PMID: 8414980
PMC: 310059.
DOI: 10.1093/nar/21.18.4259.
Multiple cytogenetically abnormal clones in two polycythemia vera patients.
Testa J, Kanofsky J, Rowley J, Baron J
Hum Genet. 1981; 57(2):165-8.
PMID: 7228027
DOI: 10.1007/BF00282014.
Relevance of trisomy 15 and other chromosome abnormalities in spontaneous AKR leukemia of mice with and without Robertsonian rearrangement.
Herbst E, Gropp A
J Cancer Res Clin Oncol. 1982; 104(3):207-18.
PMID: 7161311
DOI: 10.1007/BF00406241.
DNA content analysis by flow cytometry and cytogenetic analysis in mycosis fungoides and Sézary syndrome.
Bunn Jr P, Whang-Peng J, Carney D, Schlam M, Knutsen T, Gazdar A
J Clin Invest. 1980; 65(6):1440-8.
PMID: 6997334
PMC: 371482.
DOI: 10.1172/JCI109808.
Dual parameter flow cytometry studies in human lymphomas.
Shackney S, Skramstad K, CUNNINGHAM R, Dugas D, Lincoln T, LUKES R
J Clin Invest. 1980; 66(6):1281-94.
PMID: 6969266
PMC: 371613.
DOI: 10.1172/JCI109980.
Pathogenetic significance of "pure" monosomy 7 in myeloproliferative disorders. Analysis of 14 cases.
Pasquali F, Bernasconi P, Casalone R, Fraccaro M, Bernasconi C, Lazzarino M
Hum Genet. 1982; 62(1):40-51.
PMID: 6961098
DOI: 10.1007/BF00295602.
Tumor progression, oncogenes and the evolution of metastatic phenotypic diversity.
Nicolson G
Clin Exp Metastasis. 1984; 2(2):85-105.
PMID: 6543697
DOI: 10.1007/BF00052411.
Generation of phenotypic diversity and progression in metastatic tumor cells.
Nicolson G
Cancer Metastasis Rev. 1984; 3(1):25-42.
PMID: 6370418
DOI: 10.1007/BF00047691.
Karyotypic progression in human tumors.
WOLMAN S
Cancer Metastasis Rev. 1983; 2(3):257-93.
PMID: 6231097
DOI: 10.1007/BF00048481.
